Oup Management Co is an investment fund managing more than $58.6 billion ran by Matthew Cohen. There are currently 12 companies in Mr. Cohen’s portfolio. The largest investments include Centessa Pharmaceuticals Plc and Dice Therapeutics Inc., together worth $30.7 billion.
As of 31st July 2023, Oup Management Co’s top holding is 2,937,615 shares of Centessa Pharmaceuticals Plc currently worth over $18.2 billion and making up 31.0% of the portfolio value.
In addition, the fund holds 268,346 shares of Dice Therapeutics Inc. worth $12.5 billion.
The third-largest holding is Aerovate Therapeutics Inc. worth $10.4 billion and the next is Cyteir Therapeutics, Inc. worth $6.39 billion, with 2,459,572 shares owned.
Currently, Oup Management Co's portfolio is worth at least $58.6 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Oup Management Co office and employees reside in Bala Cynwyd, Pennsylvania. According to the last 13-F report filed with the SEC, Matthew Cohen serves as the Managing Member at Oup Management Co.
There are companies that Oup Management Co is getting rid of from its portfolio.
Oup Management Co closed its position in Ionq, Inc. on 7th August 2023.
It sold the previously owned 389,668 shares for $2.4 billion.
The two most similar investment funds to Oup Management Co are Surience Private Wealth and Rob Exploration. They manage $58.9 billion and $58.9 billion respectively.
Oup Management Co’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 13.9% of
the total portfolio value.
The fund focuses on investments in the United States as
41.7% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
17% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $180 million.
These positions were updated on August 7th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Centessa Pharmaceuticals Plc |
No change
2,937,615
|
$18,183,837,000 | 31.01% |
| Dice Therapeutics Inc. |
No change
268,346
|
$12,467,355,000 | 21.26% |
| Aerovate Therapeutics Inc. |
No change
603,762
|
$10,354,518,000 | 17.66% |
| Cyteir Therapeutics, Inc. |
No change
2,459,572
|
$6,394,887,000 | 10.91% |
| Pmv Pharmaceuticals Inc |
No change
989,232
|
$6,192,592,000 | 10.56% |
| Ionq, Inc. |
Closed
389,668
|
$2,396,458,000 | |
| Prime Medicine, Inc. |
Closed
121,255
|
$1,491,437,000 | |
| Vor Biopharma Inc. |
No change
374,714
|
$1,157,866,000 | 1.97% |
| Graphite Bio |
No change
406,308
|
$1,056,401,000 | 1.80% |
| Selecta Biosciences Inc |
No change
862,543
|
$966,048,000 | 1.65% |
| Effector Therapeutics, Inc. |
No change
1,025,697
|
$851,534,000 | 1.45% |
| Precision BioSciences, Inc. |
No change
1,123,913
|
$591,178,000 | 1.01% |
| Spero Therapeutics Inc |
No change
249,070
|
$361,152,000 | 0.62% |
| Homology Medicines Inc |
No change
64,000
|
$56,640,000 | 0.10% |
| No transactions found | |||
| Showing first 500 out of 14 holdings | |||